Guo, Yang Eric
Manteiga, John C.
Henninger, Jonathan E.
Sabari, Benjamin R.
Dall’Agnese, Alessandra
Hannett, Nancy M.
Spille, Jan-Hendrik
Afeyan, Lena K.
Zamudio, Alicia V.
Shrinivas, Krishna
Abraham, Brian J.
Boija, Ann
Decker, Tim-Michael
Rimel, Jenna K.
Fant, Charli B.
Lee, Tong Ihn
Cisse, Ibrahim I.
Sharp, Phillip A.
Taatjes, Dylan J.
Young, Richard A.
Article History
Received: 17 October 2018
Accepted: 10 July 2019
First Online: 7 August 2019
Competing interests
: R.A.Y. is a founder and shareholder of Syros Pharmaceuticals, Camp4 Therapeutics, Omega Therapeutics and Dewpoint Therapeutics. P.A.S. is a member of the board and shareholder in Syros and a member of the Scientific Advisory Board of Dewpoint. B.J.A. and T.I.L. are shareholders of Syros Pharmaceuticals. T.I.L. is a consultant to Camp4 Therapeutics and I.I.C. is a consultant to Dewpoint Therapeutics. All other authors declare no competing interests.